News
Tag: Clinical News
-
Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
BOTHELL, Washington and VANCOUVER, British Columbia, February 20, 2018 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced preliminary data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) clinical study of cytisine. The study, initiated in October 2017,…
-
Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects
BOTHELL, Wash and VANCOUVER, British Columbia, NOV. 14, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of 3mg cytisine. The study evaluated the bioavailability…
-
Achieve Announces Advancement of Cytisine Clinical Development Program
Rapid Progress on Advancing Clinical Program with Commencement of Pharmacokinetic (PK) & Pharmacodynamic (PD) Cytisine Study and Completion of Enrollment in Food Effect PK Study. BOTHELL, Wash and VANCOUVER, British Columbia, Oct. 4, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for…
-
Achieve Announces Initiation of Cytisine Clinical Development Program
BOTHELL, Wash and VANCOUVER, British Columbia, Aug. 16, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced initiation of the Cytisine Clinical Development Program. Cytisine is an established smoking cessation treatment that has been approved and marketed in…
-
Achieve Announces FDA Acceptance of the Investigational New Drug Application (IND) for Cytisine as a Smoking Cessation Treatment
Strategic Collaboration with the National Institutes of Health (NIH) Instrumental in Facilitating IND-enabling Studies. BOTHELL, Wash and VANCOUVER, British Columbia, Aug. 11, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for cytisine, an established smoking cessation treatment…